Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement.
about
Dietary interventions for mineral and bone disorder in people with chronic kidney diseaseManagement of chronic kidney disease-mineral and bone disorder: Korean working group recommendationsLanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherenceVascular calcification: When should we interfere in chronic kidney disease patients and how?Mineral bone disease in maintenance hemodialysis patients: Association with morbidity and mortality.Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study.Indian commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of chronic kidney disease-mineral and bone disorders.An optical method for serum calcium and phosphorus level assessment during hemodialysisEfficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency.Quantification of Dialytic Removal and Extracellular Calcium Mass Balance during a Weekly Cycle of Hemodialysis.Haemodialysate: long neglected, difficult to optimize, may modify hard outcomes.Sudden onset of parathyroid hormone-independent severe hypercalcemia from reversal of tumoral calcinosis in a dialysis patient.Iron Therapy Challenges for the Treatment of Nondialysis CKD PatientsGuidewire exchange vs new site placement for temporary dialysis catheter insertion in ICU patients: is there a greater risk of colonization or dysfunction?(18)F-fluoride positron emission tomography measurements of regional bone formation in hemodialysis patients with suspected adynamic bone disease.What is the impact of immunosuppressive treatment on the post-transplant renal osteopathy?Advances in pharmacotherapy for hyperphosphatemia in renal disease.Calcifediol to Treat Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Attainment of guideline targets in EURODOPPS haemodialysis patients: are differences related to a country's healthcare expenditure and nephrologist workforce?Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.Pro: cardiovascular calcifications are clinically relevant.Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis.Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Graphe3 study.Stabilization of serum alkaline phosphatase in hemodialysis patients by implementation of local chronic kidney disease-mineral bone disorder management strategy: A quality improvement study.Achievement of 2009 and 2017 Kidney Disease: Improving Global Outcomes mineral and bone targets and survival in a French cohort of chronic kidney disease Stages 4 and 5 non-dialysis patientsAchievements in CKD-MBD guidelines targets: is there a progress in the implementation practice?
P2860
Q24187142-E84927B3-18FC-4ED7-8785-83C8A176922BQ26781361-783C88DB-FE79-4EA2-A492-17481AF88E87Q27013882-F78E9D29-98E1-4F3D-BE7F-8B26286865E8Q28071582-96DD6DC2-6E35-4485-B632-E986B0B1E45FQ34186438-0B55E9F9-98C4-4DE6-AA3C-30A350226833Q34403555-66666290-16DF-41FB-A6F8-3AAC3235B168Q34435887-D481300C-C73E-4712-BEC3-17D47172AC29Q35180369-0E0F3A64-0550-4A32-A915-CB8A1636DF85Q35232708-D31E1D05-2EAA-4D40-B725-BB6774CC6B4EQ35735678-7ADCDE93-CA20-404C-B7F9-829B7BF9C450Q35988171-EC160F23-CF0A-4061-98DA-6F5375E74002Q36088902-DD768777-64B9-4BD5-886A-D23037B3D843Q36147549-AF77CEE0-51C5-4032-9BD3-F8544FC54916Q37069943-E5A9FBE5-23BC-4E3C-9211-D3E56C2F580DQ37139957-A76A8194-2D88-4ED0-B30F-F6A87769389DQ37298652-86281F05-A216-4DD3-B658-CA784D30F3FFQ38161821-05C064A2-6161-4989-8647-5C0BF7D44D40Q38587575-9C5DF084-FD76-4A10-8F6A-D33EC5A6FC3AQ38605841-66E8D57C-27AE-4A3C-9377-4B4096A48979Q38803449-C29BABD0-B669-4656-9275-A1D987C57480Q38828618-C5C7F1FC-465A-4A5B-8168-B4B6FD33B6C3Q39037212-EBA9AC75-7F2C-43A6-853E-AFEB2CBFAE66Q39374348-AC341C8E-FF7A-4FBD-9F85-3C2E0742EE02Q41354300-7B71972B-5AED-4243-B4A0-68C9B4891216Q48032432-83BC9FBD-48D0-42BF-981B-9614FD480CC8Q49433201-4D13CFF0-FB97-4371-91E7-F76B391A9F4AQ55406875-62212633-5E9F-4AE1-A79F-E9F9596EF7B9Q57053840-F2691B3B-6DD5-472F-ACFC-221492ACD2AAQ57218134-77965FE8-EA95-4815-A1F1-A7B66E9176D8
P2860
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Endorsement of the Kidney Dise ...... e (ERBP) commentary statement.
@en
Endorsement of the Kidney Disease Improving Global Outcomes
@nl
type
label
Endorsement of the Kidney Dise ...... e (ERBP) commentary statement.
@en
Endorsement of the Kidney Disease Improving Global Outcomes
@nl
prefLabel
Endorsement of the Kidney Dise ...... e (ERBP) commentary statement.
@en
Endorsement of the Kidney Disease Improving Global Outcomes
@nl
P2093
P2860
P50
P356
P1476
Endorsement of the Kidney Dise ...... e (ERBP) commentary statement.
@en
P2093
David J A Goldsmith
Francesco Locatelli
Gérard Michel London
Pablo Urena
P2860
P304
P356
10.1093/NDT/GFQ513
P407
P50
P577
2010-09-09T00:00:00Z